Duloxetine Capsule, Delayed Release Pellets
NDC Package 70518-0122-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Duloxetine (duloxetine hydrochloride) capsules is duloxetine delayed-release capsules is indicated for the treatment of:Major depressive disorder in adultsGeneralized anxiety disorder in adults and pediatric patients 7 years of age and olderDiabetic peripheral neuropathic pain in adultsFibromyalgia in adults and pediatric patients 13 years of age and olderChronic musculoskeletal pain in adults. This formulation utilizes a capsule, delayed release pellets delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-0122 and is authorized under FDA application ANDA203088.

Identification & Billing

NDC Package Code
70518-0122-2
Package Description
60 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC
Product Code
70518-0122
11-Digit Billing Format
70518012202
RxNorm Crosswalk
  • RxCUI: 596934 - DULoxetine 60 MG Delayed Release Oral Capsule
  • RxCUI: 596934 - duloxetine 60 MG Delayed Release Oral Capsule
  • RxCUI: 596934 - duloxetine 60 MG (as duloxetine HCl 67.3 MG) Delayed Release Oral Capsule

Clinical Specifications

Proprietary Name
Duloxetine Delayed-release
Non-Proprietary Name
Duloxetine Hydrochloride
Substance Name
Duloxetine Hydrochloride
Dosage Form
Capsule, Delayed Release Pellets - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DULOXETINE HYDROCHLORIDE 60 mg/1
Pharmacologic Class
Usage Information
Duloxetine delayed-release capsules is indicated for the treatment of:Major depressive disorder in adultsGeneralized anxiety disorder in adults and pediatric patients 7 years of age and olderDiabetic peripheral neuropathic pain in adultsFibromyalgia in adults and pediatric patients 13 years of age and olderChronic musculoskeletal pain in adults

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA203088
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-13-2017
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70518-0122). Click a package code to view its specific billing and regulatory data.

70518-0122-0
30 CAPSULE, DELAYED RELEASE PELLETS in 1 BLISTER PACK
70518-0122-1
30 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC
70518-0122-3
100 POUCH in 1 BOX / 1 CAPSULE, DELAYED RELEASE PELLETS in 1 POUCH (70518-0122-4)
70518-0122-5
90 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-0122-2 identifies a specific commercial package of 60 capsule, delayed release pellets in 1 bottle, plastic of Duloxetine Delayed-release, a human prescription drug labeled by Remedyrepack Inc.. This capsule, delayed release pellets is formulated for oral use and contains duloxetine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on January 13, 2017. The current certification is valid through December 31, 2027.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518012202. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-0122-2
11-Digit CMS (5-4-2)
70518-0122-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.